23:09 , May 23, 2018 |  BC Extra  |  Company News

Management Tracks: Lilly, LogicBio

Eli Lilly and Co. (NYSE:LLY) said Lilly SVP and Lilly Oncology President Sue Mahony will retire at the end of August. The pharma is searching for candidates to succeed Mahony. Gene editing company LogicBio Therapeutics...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Pfenex management update

Pfenex Inc. , San Diego, Calif.   Business: Biosimilars, Supply/Service   Hired: Paul Wagner as CFO, formerly director, portfolio manager and senior equity analyst at Allianz Global Investors  ...
08:00 , Feb 21, 2011 |  BioCentury  |  Finance

Playing the CVR

Much of the time that Genzyme Corp. and sanofi-aventis Group spent bargaining over Genzyme's acquisition was devoted to the value of Lemtrada alemtuzumab in multiple sclerosis. They finally agreed on a $14 contingent value right,...
08:00 , Feb 7, 2011 |  BioCentury  |  Finance

Contingent Thinking

Contingent thinking If investors had anything to say about the contingent value right that's presumably being discussed in the acquisition negotiations between Genzyme Corp. (NASDAQ:GENZ) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY), they would want a hefty...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

More to life than debt

The name of the game last year for financing was debt, which predominantly went to the largest companies. As long as interest rates remain low, insiders don't expect biotech appetite for debt to diminish. But...
08:00 , Dec 6, 2010 |  BioCentury  |  Finance

Dubious about prophylaxis

Buysiders showed little enthusiasm for data showing efficacy for Truvada emtricitabine/tenofovir as a prophylaxis for HIV. But at least one sellside analyst is throwing out blockbuster market projections. For its part, Gilead Sciences Inc. (NASDAQ:GILD),...
07:00 , Jun 7, 2010 |  BioCentury  |  Finance

Next Show for Prolia

After last week's FDA approval of Prolia denosumab from Amgen Inc. to treat postmenopausal osteoporosis, buysiders are focused on upcoming data and an approval in oncology, which they expect could be a more lucrative market...
07:00 , May 17, 2010 |  BioCentury  |  Finance

What to do with all that Cash

Investors polled by Ebb & Flow endorsed the new three-year, $5 billion share buyback proposed last week by Gilead Sciences Inc. (NASDAQ:GILD). At the Bank of America Merrill Lynch Healthcare conference on Thursday, Gilead President...
07:00 , Apr 26, 2010 |  BioCentury  |  Finance

End of the honeymoon?

Human Genome Sciences Inc. (NASDAQ:HGSI) stumbled last week for the first time since its meteoric climb last summer from micro- to large cap. Its shares tumbled $3.05 (10%) to $28.76, slicing the company's market cap...